Overview of the Class Action Lawsuit Against Altimmune
Levi & Korsinsky, LLP has recently informed investors about a significant class action lawsuit filed against Altimmune, Inc. This lawsuit relates to allegations of securities fraud that have impacted shareholders adversely. The firm is reaching out to potential class members to ensure that they are aware of their rights and the upcoming deadlines associated with the case.
Understanding the Class Definition
The class action aims to recover losses on behalf of all investors who purchased shares of Altimmune between August 10, 2023, and June 25, 2025. This period is critical as it encompasses the alleged fraudulent actions that misled investors regarding the company's future prospects. Shareholders potentially affected are encouraged to stay informed and active in the proceedings to safeguard their financial interests.
Recent Developments in Altimmune's Case
Recent updates reveal key details about the lawsuit. On June 26, 2025, Altimmune released crucial topline results from the IMPACT Phase 2b MASH trial pertaining to Pemvidutide for treating MASH. Prior to this announcement, the company had set high expectations among investors regarding the trial's outcomes. However, the results indicated a lack of statistical significance in the primary endpoint related to fibrosis reduction. This disappointing news led to a significant drop in Altimmune's stock price, from $7.71 to $3.61 per share, representing a staggering 53.2% decline in a single day. The market reaction highlights the severe impact of the company's omission of pertinent information on investors.
What Are the Next Steps for Affected Investors?
Affected investors are alerted to the urgency of the situation, as they have until October 6, 2025, to request appointment as lead plaintiffs in the lawsuit. It's important to note that even if an investor does not wish to serve as a lead plaintiff, they can still participate in any potential recovery resulting from the lawsuit. The law firm is ready to assist class members navigate through this process, ensuring they understand their rights.
Cost-Free Participation and Why Choose Levi & Korsinsky
For investors considering joining this lawsuit, it is essential to clarify that there are no out-of-pocket costs required to participate. Those identified as class members could qualify for compensation without any financial burden or obligation. Additionally, Levi & Korsinsky possesses a proven track record with over 20 years of experience, having secured hundreds of millions of dollars for aggrieved shareholders. The firm consistently ranks among the top securities litigation firms in the United States and is well-equipped to manage complex cases like this one.
Contact Information for Levi & Korsinsky
Investors wishing to learn more or to participate should contact Levi & Korsinsky directly. Joseph E. Levi, Esq., and Ed Korsinsky, Esq. are leading the charge on this matter. They can be reached via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. The office is located at 33 Whitehall Street, 17th Floor, New York, NY 10004.
Frequently Asked Questions
What does the class action lawsuit against Altimmune entail?
The lawsuit seeks to recover losses for investors who purchased shares during the specified time frame, alleging securities fraud that misled shareholders.
What are the key dates associated with this lawsuit?
Investors have until October 6, 2025, to request appointment as lead plaintiffs in the case.
How much does it cost to participate in the lawsuit?
There are no costs associated for class members to participate in the lawsuit. They may be entitled to compensation without any financial obligation.
Who can I contact for more information?
Interested parties should reach out to Levi & Korsinsky, specifically Joseph E. Levi, Esq., at (212) 363-7500 or via email at jlevi@levikorsinsky.com.
What should investors do if they were affected by the stock price decline?
Affected investors should act quickly to understand their rights, and they can consider joining the class action to recover their losses.
